European Countries Can Purchase Protein-Based COVID-19 Vaccines
The European Commission's Health Preparedness and Response Authority (HERA) recently signed a joint procurement Framework Contract with the company HIPRA HUMAN HEALTH to supply their protein COVID-19 vaccine.
This agreement will make the HIPRA vaccine rapidly available to the participating countries as soon as this vaccine has received a positive assessment by the European Medicines Agency.
There are 14 Member States and countries participating in this joint procurement, under which they can purchase up to 250 million doses.
Commissioner for Health and Food Safety, Stella Kyriakides, stated in a media statement on August 2, 2022, "The HIPRA vaccine adds yet another option to complement our broad vaccine portfolio for our Member States and citizens."
"An increase in vaccination and boosting is essential over the coming months."
"We are working tirelessly to make sure there are vaccines available for all."
"This is our European Health Union in action – preparing ahead and being ready to act."
The joint procurement contract with HIPRA complements an already broad portfolio of vaccines secured through the EU Vaccines Strategy, including the contracts already signed with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNTech-Pfizer, Moderna, Novavax and Valneva.
Some 4.2 billion COVID-19 doses have been secured under the EU Vaccines Strategy.
Note: This press announcement was manually curated for mobile readership.